CLiX ENRICH for Clinical Trials

CLiX ENRICH for Clinical Trials leverages Clinithink’s powerful CLiX ENRICH solution to interrogate rich patient data from within electronic medical records (EMRs), case report forms (CRFs), patient reported outcomes (PROs), clinical trial management systems (CTMS), electronic data capture (EDC) systems, trip reports and other clinical documentation systems to provide a distinct data advantage at critical points throughout the clinical trial life cycle.

Use Clinithink’s CLiX ENRICH for Clinical Trials to:

  • Increase predictability and reduce risk during bid phase feasibility assessment
  • Shorten study start-up time by speeding up subject recruitment
  • Automate retrospective information sorting for more accurate risk evaluation and mitigation during post-market surveillance
  • Feasibility

    Controlling time and costs are paramount in clinical trials. Feasibility study assessment using CLiX ENRICH for Clinical Trials provides additional sources of data with rich patient information to expand the pool of potentially eligible patients in close proximity to known sites. Robust clinical data insights enabled by Clinithink can support more accurate and effective protocol design to mitigate risks before costly adjustments need to be made, while also providing data transparency across sponsor, contract research organization (CRO) and trial sites.

  • Subject Recruitment

    Gathering patients for trials is a costly, time-consuming and predominantly manual process which negatively impacts time-to-market once products have reached Phase III clinical trials. Accessing the rich patient information contained within unstructured clinical text to identify eligible candidates can dramatically reduce the time it takes to gather sufficient patients and increase the trial’s effectiveness. CLiX ENRICH for Clinical Trials shortens screening time by providing a ranked list of patients based on trial protocol eligibility and provides optimized views of subject trial data for pharmaceutical companies, clinical trial research sites and CROs running the trials.

  • PHARMACOVIGILANCE

    Once a particular drug, device or treatment has been approved, pharmaceutical companies are obligated to capture data related to the detection, assessment, understanding and prevention of adverse effects. During Phase IV of clinical trials or pharmacovigilance/post-market surveillance, the ability to identify trends by monitoring actual use is handled manually by sorting through vast amounts of scattered unstructured text in EMRs, clinical documentation systems, registries and more. The power of CLiX ENRICH for Clinical Trials enables an automated method to vigilantly monitor, assess, analyze and manage risk beyond base compliance requirements for rigorous risk evaluation and mitigation strategies (REMS).

LEARN MORE ABOUT CLiX ENRICH

DISCOVER CLiX ENRICH for Clinical Trials

CLiX ENRICH CASE STUDIES (US)

CLiX ENRICH CASE STUDIES (UK)

A RECRUITMENT BREAKTHROUGH WITH CLiX ENRICH for Clinical Trials

NEW: Steve Coca DO from Ichan School of Medicine at Mt Sinai Presenting at SCOPE 2017